succinylated human serum albumin

Succinylated human serum albumin (Suc-HSA) is a chemically modified form of human serum albumin in which succinic anhydride is used to introduce negative charges onto the protein. This modification creates a negatively charged neo-glycoprotein that specifically binds to the positively charged V3-loop of HIV-1 gp120. By binding this region, Suc-HSA acts as an HIV-1 fusion inhibitor and blocks viral entry into host cells in vitro. In early clinical studies (Phase 1/2), it was evaluated for safety and pharmacokinetics in HIV-1-infected individuals but did not achieve sustained antiviral plasma levels at tested doses due to rapid hepatic clearance. The drug showed some increases in liver transaminases at higher or repeated doses[2][4][5].

Other names

Suc-HSASuc-HASsuccinylated HSA